Experimental injection aims to boost Chemo's punch in aggressive breast cancer
NCT ID NCT06358573
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether injecting the experimental drug INT230-6 directly into the tumor before standard chemotherapy and immunotherapy can improve outcomes for people with early triple-negative breast cancer (TNBC). About 61 participants will be randomly assigned to receive either the injection plus standard treatment or standard treatment alone. The main goal is to see if the combination leads to a higher rate of complete cancer disappearance at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INT230-6 (a combination of cisplatin, vinblastine, and a cell-penetrating molecule injected into the tumor)
What this could lead to
If successful, this approach could increase the chance of eliminating all cancer before surgery, potentially improving long-term outcomes for people with triple-negative breast cancer.
What could go wrong
This is a small, early-phase trial (61 participants) testing an experimental drug with no marketing approval. The added benefit over standard care is unproven, and side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni
RECRUITINGBellinzona, 6500, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
HOCH Health Ostschweiz
RECRUITINGSankt Gallen, 9007, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kantonsspital Baselland
RECRUITINGLiestal, 4410, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kantonsspital Graubünden
RECRUITINGChur, 7000, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kantonsspital Winterthur
RECRUITINGWinterthur, 8401, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Claraspital
RECRUITINGBasel, 4058, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
TBZO - Tumor- & Brustzentrum Ostschweiz
TERMINATEDSankt Gallen, 9016, Switzerland
-
Tumor Zentrum Aarau
TERMINATEDAarau, 5000, Switzerland
-
Universitätsspital Zürich - Klinik für Gynäkologie
RECRUITINGZurich, 8091, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact